Phase 4 Completed N=46 Randomized Double-blind Treatment

A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension

Source: ClinicalTrials.gov NCT00471380 ↗

Enrolled (actual)

Serious AEs

4.4%

Results posted

Mar 2010

Primary outcomePrimary: Intra Ocular Pressure (IOP) — 179.20; 191.89; 188.82; 196.26 mm Hg (millimeters mercury)*week

Summary

Double blind, crossover randomized, multicentric study to compare efficacy and tolerability of concomitant administration of travoprost and brinzolamide versus timolol-dorzolamide fixed combination in patients with glaucoma or ocular hypertension

Outcome Measures

Outcome	Result	p-value
PRIMARY Intra Ocular Pressure (IOP)	179.20; 191.89; 188.82; 196.26; 201.50; 191.93	—

Eligibility Criteria

Inclusion Criteria

Written informed consent
Diagnosis of bilateral Primary open angle glaucoma or ocular hypertension
Intra Ocular Pressure above 19 millimeters mercury at screening visit at 8:00 AM
Stable visual field in last 6 months
6 weeks wash out from previous topical medications

Exclusion Criteria

Age

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00471380). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.